Smallpox – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Smallpox – Pipeline Review, H2 2017’, provides an overview of the Smallpox pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Smallpox

The report reviews pipeline therapeutics for Smallpox by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Smallpox therapeutics and enlists all their major and minor projects

The report assesses Smallpox therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Smallpox

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Smallpox

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bavarian Nordic A/S

BioFactura Inc

CEL-SCI Corp

Chimerix Inc

EpiVax Inc

SIGA Technologies Inc

Tonix Pharmaceuticals Holding Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Smallpox - Overview

Smallpox - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Smallpox - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smallpox - Companies Involved in Therapeutics Development

Bavarian Nordic A/S

BioFactura Inc

CEL-SCI Corp

Chimerix Inc

EpiVax Inc

SIGA Technologies Inc

Tonix Pharmaceuticals Holding Corp

Smallpox - Drug Profiles

24a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brincidofovir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Smallpox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox [ankara] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smallpox vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tecovirimat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIR-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smallpox - Dormant Projects

Smallpox - Discontinued Products

Smallpox - Product Development Milestones

Featured News & Press Releases

Jun 16, 2017: Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE

May 31, 2017: SIGA to Present at the Jefferies Global Healthcare Conference on June 9, 2017

Apr 20, 2017: SIGA Completes Enrollment and Dosing in Final Cohort of Phase I Study of IV Formulation of TPOXX (tecovirimat) to Treat Smallpox

Mar 02, 2017: Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus

Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-801 at 9th Annual Biotech Showcase Conference

Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects

Nov 23, 2016: Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE Smallpox Vaccine

Sep 21, 2016: SIGA Announces Bankruptcy Court Approval of Transaction Under Which SIGA Will Pay PharmAthene Claim in Full

Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government

Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral

Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox

Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene

Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox

Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox

Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Smallpox, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Smallpox – Pipeline by Bavarian Nordic A/S, H2 2017

Smallpox – Pipeline by BioFactura Inc, H2 2017

Smallpox – Pipeline by CEL-SCI Corp, H2 2017

Smallpox – Pipeline by Chimerix Inc, H2 2017

Smallpox – Pipeline by EpiVax Inc, H2 2017

Smallpox – Pipeline by SIGA Technologies Inc, H2 2017

Smallpox – Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017

Smallpox – Dormant Projects, H2 2017

Smallpox – Dormant Projects, H2 2017 (Contd..1), H2 2017

Smallpox – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Smallpox, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports